Dr. Paul Trippier obtained his undergraduate degree in chemistry, drug design, and toxicology from the University of Hull in the UK and received his D.Phil. from the University of Oxford in synthetic organic chemistry under the supervision of Prof. Mark Moloney. He carried out postdoctoral research at Cardiff University, UK in antiviral drug discovery with Prof. Chris McGuigan, followed by a Postdoctoral appointment at Northwestern University, Evanston, IL where he worked with Prof. Rick Silverman to synthesize and identify the target of action of neuroprotective agents for Amyotrophic Lateral Sclerosis.
Dr. Trippier began his independent career at Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy in 2012 and received tenure and promotion to Associate Professor in 2019. In the same year he moved to the University of Nebraska Medical Center (UNMC) College of Pharmacy and the Fred and Pamela Buffett NCI-Designated Cancer Center. In 2024 he was promoted to Professor.
Dr. Trippier currently serves as the Co-Leader of the Translational Cancer Research Program at the Fred and Pamela Buffett NCI-Designated Cancer Center, is the Director of the UNMC Training Program in Alzheimer’s Disease Drug Discovery, was appointed to the Editorial Advisory Board of the Journal of Medicinal Chemistry and is the Secretary of the American Chemical Society Division of Medicinal Chemistry.
He has received multiple awards in his career including the TTUHSC Presidents Young Investigator Award, has been named a UNMC Distinguished Scientist and was awarded the 2023 Vada Kinman Oldfield Award for Research in Alzheimer’s Disease.
Dr. Trippier’s research focuses on small molecule drug discovery for cancer and neurodegenerative diseases and employing patient-derived induced pluripotent stem cells as phenotypic model systems.
Leave a Reply
You must be logged in to post a comment.